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Background: PI3K–AKT–mTOR inhibitors (PAMi) are promising anticancer treatments. Hyperglycaemia is a mechanism-based
toxicity of these agents and is becoming increasingly important with their use in larger numbers of patients.
Methods: Retrospective case-control study comparing incidence and severity of hyperglycaemia (all grades) between a case
group of 387 patients treated on 18 phase I clinical trials with PAMi (78 patients with PI3Ki, 138 with mTORi, 144 with AKTi and
27 with PI3K/mTORi) and a control group of 109 patients treated on 10 phase I clinical trials with agents not directly targeting the
PAM pathway. Diabetic patients were excluded in both groups.
Results: The incidence of hyperglycaemia was not significantly different between cases and controls (86.6% vs 80.7%, respectively,
P¼ 0.129). However, high grade (grade 3–4) hyperglycaemia was more frequent in the PAMi group than in controls (6.7% vs 0%,
respectively, P¼ 0.005). The incidence of grade 3–4 hyperglycaemia was greater with AKT and multikinase inhibitors compared
with other PAMi (Po0.001). All patients with high-grade hyperglycaemia received antihyperglycemic treatment and none
developed severe metabolic complications (diabetic ketoacidosis or hyperosmolar hyperglycemic nonketotic state). High-grade
hyperglycaemia was the cause of permanent PAMi discontinuation in nine patients.
Conclusions: PI3K–AKT–mTOR inhibitors are associated with small (6.7%) but statistically significant increased risk of high-grade
hyperglycaemia compared with non-PAM targeting agents. However, PAMi-induced hyperglycaemia was not found to be
associated with severe metabolic complications in this non-diabetic population of patients with advanced cancers.
The PI3K–AKT–mTOR (PAM) signalling pathway is involved in
essential cellular functions, including cell proliferation, differentia-
tion, metabolism, survival and angiogenesis (Schmelzle and Hall,
2000; Engelman, 2009). Mutations of the catalytic isoform p110a
gene-encoding PI3K (PIK3CA) and loss of function of the tumour
suppressor gene phosphatase and tensin homologue (PTEN), a
PI3K signalling inhibitor, lead to activation of this pathway and are
frequently observed in human cancers (Song et al, 2012). This
provided the rationale for the development of multiple molecular
targeted agents targeting key kinases, PI3K, AKT and mammalian
targets of rapamycin (mTOR) along the PAM signal transduction
pathway. mTOR inhibitors (mTORi) have been approved for the
treatment of advanced renal cell cancer (Hudes et al, 2007; Motzer
et al, 2008), postmenopausal hormone receptor-positive breast
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cancer (Baselga et al, 2012), pancreatic neuroendocrine cancer
(Yao et al, 2011) and sub-ependymal giant cell astrocytomas (Franz
et al, 2013). The licensing of mTORi clearly demonstrates the
therapeutic potential of targeting the PAM pathway for cancer
treatment.
Inhibition of this pathway also affects normal cellular functions,
including proliferation, angiogenesis, apoptosis and metabolism.
One crucial function of PAM pathway in normal cells is the
regulation of tissue metabolism and glucose homeostasis. PI3K,
AKT and mTOR are considered essential for the insulin signalling
pathway, regulating glucose uptake and glycogen synthesis (Saltiel
and Kahn, 2001). PI3K activity and in particular the p110a subunit
is critical in glucose homeostasis (Engelman et al, 2006; Foukas
et al, 2006; Luo et al, 2006). Animal studies have also demonstrated
that p110a inhibitors, but not p110b or p110d, block adipocyte
insulin-dependent glucose uptake and regulation (Falasca et al,
2007). It has also been shown that AKT regulates hepatic
glycogenolysis and glucose uptake through its substrate glycogen
synthase kinase-3 (GSK-3; Crouthamel et al, 2009). In addition,
mTOR is important for insulin production and secretion in
response to nutrients. Mammalian targets of rapamycin also
promotes beta-cell growth and proliferation in the pancreas and
subsequently increases insulin secretion and reduces blood glucose
levels (Khamzina et al, 2005; Laplante and Sabatini, 2012). In
particular, mTORC1 has a crucial role in end organ insulin uptake
and its chronic activation, as shown in preclinical models, is
associated with insulin resistance through ribosomal protein S6
kinase beta-1 (S6K1; Um et al, 2004; Khamzina et al, 2005;
Laplante and Sabatini, 2012). Finally, liver mTORC2 is essential for
insulin-induced AKT signalling regulation and its deletion or
inactivation leads to dysregulated hepatic gluconeogenesis and
glycogenolysis (Hagiwara et al, 2012). Taken together, the above
mechanisms provide a comprehensive explanation for the
observation that inhibition of PI3K–AKT–mTOR pathway can
lead to abrogated insulin function, impaired insulin secretion and
development of insulin resistance (Crouthamel et al, 2009; Houde
et al, 2010; Lamming et al, 2012; Fang et al, 2013).
Hyperglycaemia is well established as an important mechanism-
based toxicity associated with mTORi, which has led to develop-
ment of guidelines for its effective management (Busaidy et al,
2012). In patients treated with everolimus and temsirolimus in
large phase III clinical trials, incidence of all-grade hyperglycaemia
ranged between 12 and 50% with 4–22% of high-grade (G3–G4;
Hudes et al, 2007; Motzer et al, 2008; Verges et al, 2014). A recent
meta-analysis studying toxicities of allosteric mTORi showed an
increased risk of hyperglycaemia, all-grade by 2.95-fold (95% CI,
2.14, 4.05) and high-grade by 5.25-fold (95% CI, 3.07, 9.00)
(Sivendran et al, 2014).
Although an increased risk of hyperglycaemia has also been
described individually for inhibitors of PI3K, AKT and mTOR in
phase I–II clinical trials, the severity and complications of
hyperglycaemia caused by PAM pathway inhibitors as a whole,
together with its appropriate management, has not been studied
together. To address this, we have undertaken a comprehensive
retrospective case-control analysis to compare incidence and
severity of hyperglycaemia across a range of PAMi phase I trials
in our center.
PATIENTS AND METHODS
This is a retrospective case-control study of 496 patients with
advanced solid cancer treated on 28 different phase I clinical trials
at the Drug Development Unit at The Royal Marsden Hospital
(RMH) and Institute of Cancer Research, London, UK between
June 2008 and May 2013. The list of trials for cases and controls is
summarised in Table 1. Study subjects in the cases group consisted
of 387 patients treated on 18 phase I trials involving PI3K, AKT,
mTOR and multikinase PI3K/mTOR inhibitors, both as single
agents or in combination with cytotoxic chemotherapy or other
targeted agents. These trials included four trials with PI3Ki (2 pan
PI3K inhibitors, 1 PIK3a subunit and 1 PIK3b subunit-specific
inhibitor), eight trials with AKTi, five trials with dual mTORC
1/2 inhibitors and one multikinase PI3K-mTORC 1/2 inhibitor.
Also, 29 patients were treated with combination of PAMi and
either cytotoxic chemotherapy or other targeted agents not known
to increase the risk of hyperglycaemia such as EGFR and MEK
inhibitors. In particular, two of the 18 trials (13 patients) included
combinations with platinum or taxane compounds, which included
standard steroid premedication.
Furthermore, 109 patients treated on 10 single-agent targeted
therapy phase I trials not directly targeting PAM pathway were
selected as controls. To reduce the risk of selection bias for the
controls, we randomly selected these 10 trials via a sealed envelope
method and, subsequently, 109 patients randomly selected using a
random number table. Trials included in the control group
predominantly targeted growth factor receptors, DNA repair and
chromatin remodelling, angiogenesis or miscellaneous targets,
without major interactions with PAM pathway.
The control sample size (n¼ 109) was calculated applying a
bilateral statistical analysis with type I error probability equal to
0.05, power equal to 80% and with an assumption of predicted
odds ratio of 4 for grade 3–4 hyperglycaemia in less than 5% of
patients in the control group.
We analysed fasting blood glucose level at baseline and the
highest blood glucose (fasting or non-fasting) on study to enable us
to capture hyperglycaemia at different time points of the day. We
analysed the incidence of all-grade and high-grade hyperglycaemia,
defined as per NCI CTCAE v 4.0, with a blood glucose level of
more than 13.9mmol l 1, requiring treatment according to trial
protocols and hospital guidelines.
We only included patients on PAMi trials for which the study
results either had been published or presented in scientific
meetings. The project proposal was reviewed and approved by
the Institutional Audit Committee (DDU056).
As well as patients’ demographics, tumour characteristics and
treatment data, baseline and highest blood glucose levels during
trial were collected. In addition, we collected data on drug
interruptions or dose reductions due to hyperglycaemia. Baseline
characteristics were well balanced between both study groups as
Table 1. Phase I clinical trials in cases and controls
Cases Controls
Target
No. of
trials
No. of
patients Target
No. of
trials
No. of
patients
PI3K 4 78 (20.1%) c-MET 1 20 (18.3%)
AKT 8 144 (37.2%) HSP90 1 10 (9.2%)
mTORC 5 138 (35.6%) MEK 1 12 (11%)
Multikinase
PI3K/mTORC
1 27 (6.9%) VEGF 2 26 (23.8%)
EGFR 1 23 (21.1%)
HDAC 2 13 (11.9%)
INTEGRIN 1 4 (3.6%)
IGF-1R 1 1 (0.9%)
Total 18 387 Total 10 109
Case group: 18 phase I clinical trials of PI3K–AKT–mTOR inhibitors single agents and in
combination with chemotherapy or other targeted therapies. Control group: 10 phase I
clinical trials with agents not known to predominantly inhibit PI3K–AKT–mTOR pathway.
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shown in Table 2. Furthermore, no diabetic patients have been
included for the analysis both in cases and controls.
All data were extracted from hospital electronic patients’
records, anonymised, entered into an Access database (Microsoft,
USA) and exported into SPSS (IBM Corp., Version 19.0) for data
analysis. Categorical variables were compared by the w2-test. For
continuous variables, mean values were compared by Student’s
test. Where needed, data were log-transformed before statistical
comparisons. Correlation between glucose and not normally
distributed variables as glycosylated haemoglobin (HbA1c), insulin
and c-peptide, was studied with Spearman’s test (Supplementary
Figures 1–3). The probability to develop high-grade hyperglycae-
mia according to PAMi type was studied by multivariable binary
logistic regression analysis, correcting for other relevant potential
explanatory covariates in our data set. Proportions and point
estimates are reported together with 95% confidence intervals (CI).
RESULTS
Patient characteristics. This study patient population reflects
typical phase I patients as previously described from our institution
(Molife et al, 2012). Median age at time of recruitment to trial was
59.7 years for the cases and 56.3 years for controls. Other baseline
characteristics such as age, sex, BMI, tumour type, performance
status (PS), RMH prognostic score (Arkenau et al, 2008) were also
balanced between cases and controls. Most of the patients had a PS
of 1 or 2 with a RMH score of 0 to 1. Most common tumour types
were colorectal, gynaecological and lung malignancies. Of note,
cases comprised more gynaecological tumours compared with
controls, however, this has not any effect on the risk of developing
hyperglycaemia.
Importantly, inclusion criteria for PAMi trials exclude diabetic
patients. For this reason, only non-diabetic patients were entered
into random selection method for the control group. Median
duration of time on trials was 94.6 (range 1–1096) days for the
cases, and 124.7 (range 1–1096) days for the controls.
Glucose and related blood tests. In addition to glucose, data was
available for HbA1c, insulin and c-peptide for 340, 336 and 318
patients treated with PAM inhibitors, respectively. As expected,
there was a correlation between glucose and HbA1c, insulin and
c-peptide; P¼ 0.005, Po0.0001 and Po0.0001, respectively
(Supplementary Figures 1–3). We did not have data for these
parameters for the control group of trials of non-PAM inhibitors
thus comparison was not possible.
Increased risk of hyperglycaemia with PAM inhibitors. The
mean fasting glucose value at baseline (before receiving the first
dose of the study drug in each trial) was within the normal range
(upper limit of normal 6mmol l 1) but significantly lower in
the PAMi group compared with the control group, 5.4mmol l 1
(95% CI 5.3–5.5) vs 5.7mmol l 1 (95% CI 5.5–5.8; P¼ 0.001). The
mean highest blood glucose value during exposure to study drugs
was significantly higher in the PAMi group 8.6mmol l 1 (95% CI
8.2–9.1) vs 7.1mmol l 1 (95% CI 6.8–7.4) in the control group,
P¼ 0.001 (Figure 1). However, there was no significant difference in
the incidence of all-grade hyperglycaemia between cases (86.6%) and
controls (80.7%; OR: 1.54, 95% CI: 0.88–2.69, P¼ 0.129). Impor-
tantly, a significantly higher number of patients treated with PAMi
developed grade 3–4 hyperglycaemia compared with the control
group, 26/387 (6.7%) vs 0/109 (0%), P¼ 0.129 (Table 3).
Although the incidence of all-grade and high-grade hypergly-
caemia was 86.6% and 6.7% in the case group, respectively, only a
minority of patients (26/387 patients, 7%) needed treatment for
persistent grade 3–4 hyperglycaemia after dosing with PAMi.
Metformin (500–1000mg daily) was sufficient to achieve good
glycemic control in the majority of cases (22 patients, 5.7%). Only
4 patients (1%) required higher doses of metformin (up to 3000mg
per day). Metformin was usually prescribed according to the PAMi
treatment schedule, for example, continuously with the continuous
schedule and on dosing days in the intermittent schedule trials,
achieving an effective glycemic control within few days. Only two
Table 2. Baseline patient clinical characteristics
Cases Controls
N 387 109
Sex
Female 193 (49.9%) 53 (48.6%)
Male 194 (50.1%) 56 (51.4%)
Age, year median (range) 59.7 (22.25–81.08) 56.3 (17.49–88.3)
BMI, kgm2 median (range) 25.93 (15–43) 27.33 (15–40)
Performance status
0 106 (27.4%) 25 (22.9%)
1 277 (71.6%) 82 (75.3%)
2 4 (1.0%) 2 (1.8%)
Number of previous lines of
chemotherapy
2 (0–11) 2 (0–11)
Tumour type
Lung and mesothelioma 48 (12.4%) 11 (10.1%)
Colorectal 99 (25.6%) 16 (14.7%)
Gynaecological (ovarian,
cervical, endometrial)
59 (15.2%) 6 (5.5%)
Breast 33 (8.5%) 15 (13.8%)
Prostate 22 (5.7%) 10 (9.2%)
RCC 17 (4.4%) 3 (2.8%)
Others 109 (28.2%) 48 (44.0%)
RMH scorea
0 85 (22.0%) 25 (22.9%)
1 129 (33.3%) 32 (29.4%)
2 107 (27.6%) 32 (29.4%)
3 52 (13.5%) 20 (18.3%)
Unknown 14 (3.6%) –
Time on trial (days) 94.61 (1–1524) 124,75 (1–1096)
Abbreviations: BMI¼body mass index; RMH¼The Royal Marsden Hospital. Baseline
characteristics such as age at the time of recruitment, tumour type, number of previous lines
of chemotherapy and performance status were balanced between cases and controls.
aRMH score: albuminþ number metastatic sitesþ LDH.
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Figure 1. Baseline serum glucose levels and highest serum glucose
levels during study drug exposure according to group.
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patients (0.5%) required addition of a second oral hypoglycaemia
agent and four (1%) required short-acting insulin. The study drug
had to be withheld in nine patients (2.3% of the cases) due to high-
grade hyperglycaemia. Also hyperglycaemia was reported as a
dose-limiting toxicity (DLT) in 5 patients (1.3%) as per protocol
guidelines.
The majority (63%) of patients in the case group developed
hyperglycaemia during the first cycle of treatment. The highest
hyperglycemic levels in 75% of patients were detected during the
first cycle of treatment with PAM pathway inhibitors either as
single agents or combination with chemotherapy or other targeted
agents. Only 25% of patients presented with hyperglycaemia
beyond cycle two of treatment.
Of note, preliminary analysis of the two trials (Molife et al, 2014;
Roda et al, 2014) that included combinations with taxanes or
platinum did not show major effect of the required standard
steroid premedication on the overall toxicity profile.
Complications of hyperglycaemia. Although hyperglycaemia is
well described with some PAMi, it is not known if prolonged use of
these agents can be associated with complications such as diabetic
ketoacidosis. In this study group, following treatment with PAMi,
only four patients (1%) had evidence of glycosuria and three
patients (0.8%) of ketonuria. More importantly, ketonuria was not
combined with metabolic acidosis or hypotension (classically
associated with diabetic ketoacidosis), nor was it associated with
abnormal serum electrolytes. Also, no patients developed symp-
toms of a hyperosmolar hyperglycemic nonketotic coma. No
patients had to be admitted in hospital due to complications of
hyperglycaemia.
Comparing different classes of PAM inhibitors. We also
investigated if hyperglycaemia could be more prevalent with a
specific kinase inhibitor of the PAM pathway. For this analysis
controls were excluded. The proportion of patients developing
grade 3–4 was significantly different between different PAMi
Po0.001 (Table 4). Therefore, multivariable logistic regression
models were used to study the association between different types
of PAMi and incidence of high-grade hyperglycaemia after
correcting for potential covariates in our data set. Results are
summarised in Table 5 and demonstrate that patients on AKT and
multikinase inhibitors are at higher risk of developing grade 3–4
hyperglycaemia.
DISCUSSION AND CONCLUSIONS
Agents inhibiting PI3K–AKT–mTOR pathway are currently at
different stages of clinical development, with some already
approved for advanced cancers. Metabolic complications asso-
ciated with these agents, including hyperglycaemia and hyperlipi-
demia, are usually considered as on-target toxicities (Busaidy et al,
2012). Hyperglycaemia has been largely described with first-
generation selective allosteric mTORi, everolimus and temsiroli-
mus (Hudes et al, 2007; Motzer et al, 2008; Sivendran et al, 2014;
Table 3. Incidence of all grades and high-grade hyperglycaemia in cases (PAM inhibitors) and controls (non-PAM inhibitors)
All grades hyperglycaemia Grade 3 and 4 hyperglycaemia
Total No Yes P-valuea No Yes P-valuea
Cases n (%) 387 (100) 52 (13.4) 335 (86.6) 0.129 361 (93.3) 26 (6.7) 0.005
95% CI – 10.4%–17.2% 82.8%–89.6% 90.3%–95.4% 4.6%–9.7%
Controls n (%) 109 (100) 21 (19.3) 88 (80.7) 109 (100) 0 (0)
95% CI 13.0%–27.7% 72.3%–87.0% 96.6%–100% 0%–3.4%
Abbreviation: CI¼ confidence interval.
aw2-test.
Table 4. Incidence of hyperglycaemia between different inhibitors of the PI3K/Akt/mTOR (PAM) pathway
All-grade hyperglycaemia High-grade hyperglycaemia
Incidence Total No Yes P-valuea No Yes P-valuea
PI3K inhibitors, N (%) 78 (100) 16 (20.5) 62 (79.5) 0.053 77 (98.7) 1 (1.3) o0.001
95% CI 13.0%–30.8% 69.2%–87.0% 0.2%–7.0%
mTORC 1 or 2 inhibitors, N (%) 138 (100) 18 (13.0) 120 (86.7) 135 (97.8) 3 (2.2)
95% CI 8.4%–19.7% 80.3%–91.6% 93.8%–99.3% 0.7%–6.2%
AKT inhibitors, N (%) 144 (100) 18 (12.5) 126 (87.5) 128 (88.9) 16 (11.1)
95% CI 8.1%–18.9% 81.1%–91.9% 82.7%–93.0% 7.0%–17.3%
Multikinase inhibitors, N (%) 27 (100) 0 (0) 27 (100) 21 (77.8) 6 (22.6)
95% CI 0%–12.5% 87.5%–100% 59.2%–89.4% 10.6%–40.8%
Abbreviation: CI¼ confidence interval.
aw2-test.
Table 5. Multivariate logistic regression analysis of factors
associated with increased risk of grade 3–4 hyperglycaemia in
patients receiving PAM inhibitors
Variable OR 95% CI P-value
Type of PAM inhibitor – 0.002
PI3K inhibitors 1.0 – –
TORC 1/2 inhibitors 1.08 0.01–12.25 0.950
AKT inhibitors 9.27 1.19–72.46 0.034
Multikinase inhibitors 17.57 1.94–158.80 0.011
Gender (female vs male) 0.74 0.28–1.98 0.545
Age (continuous variable) 0.960 0.92–0.100 0.037
BMI (continuous variable) 0.999 0.98–1.02 0.899
Hypertension (yes vs not) 1.528 0.32–7.36 0.597
Fasting glucose at baseline (continuous
variable)
1.148 0.60–2.20 0.679
Abbreviations: CI¼ confidence interval; OR¼odds ratio; PAM¼PI3K–AKT–mTOR. In ‘Type
of PAM inhibitor’, PI3K inhibitors are used as the reference group.
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Verges et al, 2014). However, we sought to determine the risk and
complications of hyperglycaemia with a second generation of
PAMi. In comparison with first-generation mTORi, PIK3a
subunit-specific inhibitors, such as BYL719, are associated with a
higher risk of hyperglycaemia described in literature as frequent as
49% of cases, particularly with higher doses. Although very
frequent, in our experience hyperglycaemia is usually reversible
with oral antihyperglycemic therapy or sometimes with short-term
drug interruption (Gonzalez-Angulo et al, 2013). Drugs targeting
all isoforms of PI3K (pan-PI3Ki) such as GDC-0941 (Garcia et al,
2011), BKM120 (Rodon et al, 2014) and CH5132799 (Blagden
et al, 2014) are associated with varying degrees of hyperglycaemia,
ranging from o10% in patients treated with GDC0941 to 430%
with BKM120 (8% of high-grade). Hyperglycaemia with some
pan-PI3Ki such as CH5132799 is dose dependent (Blagden et al,
2014). Conversely, other pan-PI3Ki, such as SAR245408 (Shapiro
et al, 2014) and PX-866 (Hong et al, 2012), are not associated with
a significant increase in blood glucose level.
Data regarding the risk of hyperglycaemia with AKTi are still at
preliminary stages and again indicates the variability between
different drugs. For example, the allosteric AKTi MK2206 has been
associated with low-grade and transient hyperglycaemia (Yap et al,
2011; Molife et al, 2014). However, hyperglycaemia was more
frequent with AKT kinase inhibitors such as AZD5363 (Banerji
et al, 2013) and GDC-0068. The high incidence of hyperglycaemia
in our data set is consistent with these findings. Furthermore
another AKTi, the GSK690693 (Crouthamel et al, 2009), was
significantly associated with hyperglycaemia in animal models and
this limited its further clinical development.
Published or presented data of mTORC1/2 inhibitors such as
AZD2014 (Banerji et al, 2012), INK-128 (Infante et al, 2012;
Tabernero et al, 2012) and DS-3078a (Capelan et al, 2013) suggest
that incidence of hyperglycaemia is not much different from first-
generation mTORi. Data about INK-128 (Infante et al, 2012;
Tabernero et al, 2012), comparable with our data set, reported
hyperglycaemia as a frequent toxicity with an incidence of 44% for
all-grade and 4% for high-grade with intermittent schedule.
Significantly higher was the hyperglycaemia with the continuous
dose schedule (88% for all-grade and 16% for high-grade). The
mTORC1/2i AZD2014 (Banerji et al, 2012), has shown a
comparatively lower incidence of hyperglycaemia (9%) while the
incidence of all-grade hyperglycaemia for DS-3078a (Capelan et al,
2013) was 17%.
In this retrospective case-control study, we report that
inhibition of different nodes in the PAM pathway is associated
with significantly increased risk of high-grade hyperglycaemia
(reported in 7% of the patients), compared with the control group
treated with agents not directly targeting this pathway. All
hyperglycemic events including high-grade events have always
been clinically completely asymptomatic and transient. Impor-
tantly, high-grade hyperglycaemia was not associated with severe
metabolic complications (no patients developed diabetic ketoaci-
dosis or hyperosmolar hyperglycemic nonketotic state or showed
marked electrolyte alterations). Treatment with usual therapeutic
doses of metformin on dosing days of PAMi was sufficient to
successfully treat hyperglycaemia.
A limited number of other factors predisposing to hypergly-
caemia such as BMI and fasting glucose level were looked at and
were not found to be significantly influencing grade 3–4
hyperglycaemia. It is important to note that inclusion criteria in
phase I studies of PAMi excluded diabetics and we chose a cohort
of non-diabetic controls and there is potential to significantly
higher grade 3–4 hyperglycaemia, if diabetics were included.
Interestingly hyperglycaemia was observed more significantly with
multikinase inhibitors and AKTi but not mTORi when compared
to PI3Ki. The biological reasons for these differences are not yet
completely known. This information will need to be confirmed in
larger cohorts, however, it is important information that can be
used in the choice of which PAMi to use as single agent or in
combination studies. Although a well-described on-target toxicity
of PAMi, hyperglycaemia was reported, in our study, as a DLT in a
minority of patients (5/387, 1.3%) leading to drug discontinuation
in only 9 patients (2.3%).
In conclusion, our data confirm that hyperglycaemia with PAM
pathway inhibitors is a common and manageable toxicity in non-
diabetic cancer patients. There are subtle differences in the
incidence of hyperglycaemia depending on the specific targets
within the PAM pathway. Hyperglycaemia is an important but not
a limiting factor to the further development of these drugs as single
agents or in combination therapies.
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